Concepedia

The safety profile of infliximab in patients with Crohn’s disease: The Mayo Clinic experience in 500 patients

Jean‐Frédéric Colombel, Edward V. Loftus, William J. Tremaine, Laurence J. Egan, William S. Harmsen, Cathy D. Schleck, Alan R. Zinsmeister, William J. Sandborn

Gastroenterology · 2003 · 908 citations · 35 references

DOIFull text

Open access

Concepts

References

35

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein et al. · The Lancet · 2002 · 4.2K citations

, , +12

Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent

Joseph Keane, Sharon K. Gershon, Robert P. Wise et al. · New England Journal of Medicine · 2001 · 3.7K citations · Full text

, , +16

A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

Stephan R. Targan, Stephen B. Hanauer, Sander J. H. van Deventer et al. · New England Journal of Medicine · 1997 · 3.2K citations · Full text

, , +12

Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease

Daniel H. Present, Paul Rutgeerts, Stephan Targan et al. · New England Journal of Medicine · 1999 · 2.7K citations · Full text

, , +14

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

Filip Baert, Maja Noman, Séverine Vermeire et al. · New England Journal of Medicine · 2003 · 2K citations · Full text

, , +17